Immunohistochemical staining of Wilms Tumor 1 Protein  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Wilms Tumor 1 Protein [6F-H2] Antibody (cGMP).

$ 145.00$ 675.00
Please Select Product Options Below To View The Catalog Number.

SKU: QIVD212
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG1

Product NumberDescriptionPrice
QIVD212-0.1ml Size: 0.1 ml, Format: Concentrate $ 145.00
QIVD212-0.5ml Size: 0.5 ml, Format: Concentrate $ 415.00
QIVD212-1ml Size: 1 ml, Format: Concentrate $ 675.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QIVD212-0.1ml
Wilms Tumor 1 Protein General Information
Alternate Names
Molecular Weight
49.2 kDa
Chromosomal Location
p13 [chr: 11] [chr_start: 32387775] [chr_end: 32435885] [strand: -1]
Curated Database and Bioinformatic Data
Gene SymbolWT1
Entrez Gene ID7490
RefSeq Protein Accession(s)NP_077742; NP_001185481; NP_000369; NP_001185480; NP_077744
RefSeq mRNA Accession(s)NM_024426; NM_001367854; NM_024425; NM_001198551; NM_001198552; NM_024424; NM_000378; NR_160306
RefSeq Genomic Accession(s)NC_000011; NG_009272;
UniProt ID(s)P19544
PharmGKB ID(s)PA37395
KEGG Gene ID(s)hsa:7490
Associated Diseases (KEGG IDs)Frasier syndrome (FS) [MIM:136680]: Characterized by a slowly progressing nephropathy leading to renal failure in adolescence or early adulthood, male pseudohermaphroditism, and no Wilms tumor. As for histological findings of the kidneys, focal glomerular sclerosis is often observed. There is phenotypic overlap with Denys-Drash syndrome. Inheritance is autosomal dominant. {ECO:0000269|PubMed:10571943}. The disease is caused by mutations affecting the gene represented in this entry.; Wilms tumor 1 (WT1) [MIM:194070]: Embryonal malignancy of the kidney that affects approximately 1 in 10'000 infants and young children. It occurs both in sporadic and hereditary forms. {ECO:0000269|PubMed:1317572, ECO:0000269|PubMed:15150775, ECO:0000269|PubMed:9108089, ECO:0000269|PubMed:9529364}. The disease is caused by mutations affecting the gene represented in this entry.; Denys-Drash syndrome (DDS) [MIM:194080]: Typical nephropathy characterized by diffuse mesangial sclerosis, genital abnormalities, and/or Wilms tumor. There is phenotypic overlap with WAGR syndrome and Frasier syndrome. Inheritance is autosomal dominant, but most cases are sporadic. {ECO:0000269|PubMed:10738002, ECO:0000269|PubMed:10799199, ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:11519891, ECO:0000269|PubMed:1302008, ECO:0000269|PubMed:1338906, ECO:0000269|PubMed:15349765, ECO:0000269|PubMed:1655284, ECO:0000269|PubMed:8111391, ECO:0000269|PubMed:8112732, ECO:0000269|PubMed:8295405, ECO:0000269|PubMed:8388765, ECO:0000269|PubMed:8411073, ECO:0000269|PubMed:8741319, ECO:0000269|PubMed:8956030, ECO:0000269|PubMed:9475094, ECO:0000269|PubMed:9529364}. The disease is caused by mutations affecting the gene represented in this entry.; Nephrotic syndrome 4 (NPHS4) [MIM:256370]: A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show non-specific histologic changes such as focal segmental glomerulosclerosis and diffuse mesangial proliferation. Some affected individuals have an inherited steroid-resistant form and progress to end-stage renal failure. Most patients with NPHS4 show diffuse mesangial sclerosis on renal biopsy, which is a pathologic entity characterized by mesangial matrix expansion with no mesangial hypercellularity, hypertrophy of the podocytes, vacuolized podocytes, thickened basement membranes, and diminished patency of the capillary lumen. {ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:15253707, ECO:0000269|PubMed:20798252, ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189}. The disease is caused by mutations affecting the gene represented in this entry.; Meacham syndrome (MEACHS) [MIM:608978]: Rare sporadically occurring multiple malformation syndrome characterized by male pseudohermaphroditism with abnormal internal female genitalia comprising a uterus and double or septate vagina, complex congenital heart defect and diaphragmatic abnormalities. {ECO:0000269|PubMed:17853480}. The disease is caused by mutations affecting the gene represented in this entry.; A chromosomal aberration involving WT1 may be a cause of desmoplastic small round cell tumor (DSRCT). Translocation t(11;22)(p13;q12) with EWSR1.; Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. {ECO:0000269|PubMed:8401592}. The disease may be caused by mutations affecting the gene represented in this entry.
General Description of Wilms Tumor 1 Protein .
Wilms tumor-1 (WT-1), is a gene involved in the induction of Wilms tumor, a pediatric renal malignancy. Wilms tumor is associated with mutations of WT1, a zinc-finger transcription factor that is essential for the development of the metanephric kidney and the urogenital system. The WT1 gene is normally expressed in fetal kidney and mesothelium, and its expression has been suggested as a marker for Wilms tumor and mesothelioma.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:50-1:100
Pretreatment EDTA Buffer pH 8.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal
Anti-Wilms Tumor 1 Protein Antibody Clone: 6F-H2
Host and Isotype: Mouse IgG1
Recommended Positive Control Sample: Wilms tumor
Cellular Localization of Antibody 6F-H2 Staining: Cytoplasmic, nuclear
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: BALB/C mice were injected with truncated human WT1 protein corresponding to N-terminal amino acids 1-181.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Wilms Tumor 1 Protein Information for Pathologists

Summary:

Tumor suppressor gene at 11p13. Protein is transcriptional regulator that apparently inhibits transcription of growth promoting genes. Involved in development of tissues from inner layer of intermediate mesoderm. Interpretation Nuclear stain.

Common Uses By Pathologists:

Ovarian carcinoma (WT1+) vs. breast/pancreatic carcinoma (WT1 negative). Positive staining - normal Fallopian tube, kidney, mesothelium, ovarian granulosa cells, Sertoli cells, spleen. Positive staining - disease Acute myeloid leukemia, cystic partially differentiated nephroblastoma, desmoplastic small round cell tumor, malignant mesothelioma, metanephric adenoma, nephrogenic rests, ovarian carcinomas (serous carcinoma [almost all], transitional, small cell, Am J Surg Pathol 2005;29:1034), peritoneal serous carcinoma involving an endometrial polyp-80% (Am J Surg Pathol 2005;29:1074), rhabdoid tumor, Wilm tumor.

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “Wilms Tumor 1 Protein [6F-H2] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Chat: See lower right corner. | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Wilms Tumor 1 Protein [6F-H2] Antibody (cGMP).